Latest Publications


Bristol-Myers Squibb Co. v. Teva Pharms. USA, Inc.

Nature of the Case and Issue(s) Presented: BMS owns the ’244 patent, which covers a nucleoside analogue composed of two regions: a carbocyclic ring and a guanine base. Nucleoside analogues are known to mimic the activity of...more


Clones Not Patent-Eligible?

Thanks to recent advances in cloning technology, treating degenerative diseases with replacement tissue that matches a patient’s genetic makeup exactly is no longer science fiction. Just last month, for example, two research...more

5/9/2014 - DNA Medical Research Myriad Patent Trial and Appeal Board Patent-Eligible Subject Matter Patents Stem cells USPTO

GENERICally Speaking - Vol. 4, No. 1

The Hatch-Waxman Litigation and Life Sciences practice groups at Robins, Kaplan, Miller & Ciresi L.L.P. are pleased to offer the latest edition of their quarterly publication regarding ANDA patent litigation issues and the...more

4/1/2014 - ANDA Burden of Proof Claim Construction Claim Preclusion Eli Lilly FDA Federal Rule 12(b)(6) GlaxoSmithKline Hatch-Waxman Inter Partes Reexamination Obviousness Patent Infringement Patent Litigation Patent-in-Suit Patents Pfizer Pharmaceutical Pharmaceutical Patents Prior Art Settlement Subject Matter Jurisdiction Written Descriptions

3 Results
View per page
Page: of 1